<DOC>
	<DOC>NCT00311532</DOC>
	<brief_summary>The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line therapy. The secondary objective of the study is to estimate the prevalence of valvulopathy, as determined by baseline echocardiograms, among all patients who have Parkinson's Disease and are being considered for pergolide as second-line therapy.</brief_summary>
	<brief_title>Observational Study of Pergolide Mesylate and Cardiac Valvulopathy</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Pergolide</mesh_term>
	<criteria>Male or female, age 18 and older with a diagnosis of Parkinson's Disease Receiving pergolide as secondline therapy as prescribed by Summary of Product Characteristics Willing to participate and sign a consent to release medical information Have had an echocardiogram within 3 months of initiation of pergolide therapy with no evidence of cardiac valvulopathy There are no exclusion criteria for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>